scholarly journals Long-Term Follow-Up of a Phase I/II Study of ProSavin, a Lentiviral Vector Gene Therapy for Parkinson's Disease

2018 ◽  
Vol 29 (3) ◽  
pp. 148-155 ◽  
Author(s):  
Stéphane Palfi ◽  
Jean Marc Gurruchaga ◽  
Hélène Lepetit ◽  
Katy Howard ◽  
G. Scott Ralph ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Phase I ◽  
Lentiviral Vector ◽  
Long Term Follow Up

scholarly journals Long-term follow-up of a randomized AAV2-GAD gene therapy trial for Parkinson’s disease

JCI Insight ◽  
2017 ◽  
Vol 2 (7) ◽  
Author(s):  
Martin Niethammer ◽  
Chris C. Tang ◽  
Peter A. LeWitt ◽  
Ali R. Rezai ◽  
Maureen A. Leehey ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Gene Therapy Trial ◽  
Long Term Follow Up ◽  
Therapy Trial

Long term follow-up in advanced Parkinson’s disease treated with DBS of the subthalamic nucleus

2021 ◽  
Author(s):  
Maria Antonietta Volonté ◽  
Giacomo Clarizio ◽  
Sebastiano Galantucci ◽  
Pietro Giuseppe Scamarcia ◽  
Rosalinda Cardamone ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Subthalamic Nucleus ◽  
Advanced Parkinson’S Disease ◽  
Long Term Follow Up

Congenital erythropoietic porphyria and Parkinson's disease: clinical association in a patient with a long-term follow-up

2011 ◽  
Vol 21 (4) ◽  
pp. 613-614 ◽  
Author(s):  
Esteve Darwich ◽  
Antonio Guilabert ◽  
Azahara Aceituno ◽  
Natàlia Mas ◽  
Jordi To-Figueras ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Congenital Erythropoietic Porphyria ◽  
Long Term Follow Up

Long-Term Follow-Up Results of Stereotactic Adrenal Medullary Transplantation in Parkinson's Disease

1994 ◽  
Vol 62 (1-4) ◽  
pp. 141-147 ◽  
Author(s):  
Sang Sup Chung ◽  
Yong Gou Park ◽  
Jin Woo Chang ◽  
Joon Cho
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Long Term Follow Up

Long-term follow-up results of selective VIM-thalamotomy

1986 ◽  
Vol 65 (3) ◽  
pp. 296-302 ◽  
Author(s):  
Yoshishige Nagaseki ◽  
Tohru Shibazaki ◽  
Tatsuo Hirai ◽  
Yasuhiro Kawashima ◽  
Masafumi Hirato ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Essential Tremor ◽  
The Other ◽  
Content Type ◽  
Early Results ◽  
Initial Surgery ◽  
Long Term Follow Up

✓ The authors report the results of a long-term follow-up study of the effects of the physiologically defined selective VIM (nucleus ventralis intermedius)-thalamotomy on tremor of Parkinson's disease in 27 patients and essential tremor in 16 patients. The follow-up period ranged from 3.25 to 10 years (mean 6.58 years). In 43 patients a total of 50 operations (including four bilateral operations and three reoperations) were carried out. The early (2 to 4 weeks after surgery) and late effects on the tremors were determined clinically and electromyographically. Fourteen parkinsonian cases were treated with minimal lesions (about 40 cu mm). Their late results were very similar to the early results: in 10, the tremors were completely abolished, three had a slight residual tremor, and one underwent reoperation 3 months after the first surgery. Eleven essential tremor cases were treated with minimal lesions. Six of these tremors were completely abolished, four patients had slight residual tremors, and one patient with a recurrence underwent reoperation 2 years after the initial surgery. In these 23 successful operations with minimal lesions (excluding two cases with reoperation), the tremor was abolished without discernible long-lasting side effects. The other 23 operations on 16 patients with Parkinson's disease (including one reoperation) and on seven with essential tremor (one of whom also had a minimal lesion on the other side) involved relatively large lesions. In this group, the surgery was successful in almost every case. It was concluded that radiographically and physiologically monitored selective VIM-thalamotomy for parkinsonian and essential tremor is effective even when lesioning is minimal. Moreover, the beneficial effect is maintained over a long period of time.

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

The Lancet ◽  
2014 ◽  
Vol 383 (9923) ◽  
pp. 1138-1146 ◽  
Author(s):  
Stéphane Palfi ◽  
Jean Marc Gurruchaga ◽  
G Scott Ralph ◽  
Helene Lepetit ◽  
Sonia Lavisse ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Gene Therapy ◽  
Parkinson's Disease ◽  
Dose Escalation ◽  
Lentiviral Vector ◽  
Phase 1 ◽  
Open Label ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document